Article in Science translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Brittany LipchickMolecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.ORCID 0000-0002-7326-0079
Adam N GuterresMolecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.ORCID 0000-0002-4607-2099
Hsin-Yi ChenMolecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.
Delaine M ZundellMolecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.
Segundo Del AguilaMolecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.ORCID 0000-0003-3221-8234
Patricia I Reyes-UribeMolecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.
Yulissa TiradoMolecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.ORCID 0009-0006-4035-4665
Subhasree BasuMolecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.ORCID 0009-0008-0969-800X
Xiangfan YinMolecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.
Andrew V KossenkovMolecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.ORCID 0000-0002-1536-0418
Yiling LuDepartment of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-3662-2106
Gordon B MillsDivision of Oncological Sciences, Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR 97239, USA.ORCID 0000-0002-0144-9614
Qin LiuMolecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.ORCID 0000-0001-9964-580X
Aaron R GoldmanMolecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.ORCID 0000-0001-7605-9592
Maureen E MurphyMolecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.
David W SpeicherMolecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.
Jessie VillanuevaMolecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.ORCID 0000-0001-5701-2609
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2008 to 2023
$37.1M
TRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3M
Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic MachineryU54CA224070 · NCI · WISTAR INSTITUTE · PI Michael Davies · 2017 to 2026
$13.9M
Targeting exosomal PDL1 to improve immunotherapyP50CA261608 · NCI · WISTAR INSTITUTE · PI VILLANUEVA, JESSIE · 2021 to 2025
$11.3M
STRUCTURAL BIOLOGY TRAINING PROGRAMT32GM008275 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI WAND, A. JOSHUA · 1988 to 2018
$6.0M
Targeting S6K2 to Overcome Drug Resistance in NRAS-mutant MelanomaR01CA268510 · NCI · WISTAR INSTITUTE · PI VILLANUEVA, JESSIE · 2022 to 2025
$2.4M
Integrative Approach to Comprehensive Analysis of High Throughput Data on a Cancer Center LevelR50CA211199 · NCI · WISTAR INSTITUTE · PI Andrew V Kossenkov · 2016 to 2026
$1.6M
Purchase of a Q Exactive HF mass spectrometer system for metabolomicsS10OD023586 · OD · WISTAR INSTITUTE · PI SPEICHER, DAVID W. · 2017 to 2017
Although oncogenic NRAS activates mitogen-activated protein kinase (MAPK) signaling, inhibition of the MAPK pathway is not therapeutically efficacious in
Indexed as
Drug Resistance, NeoplasmGTP PhosphohydrolasesHomeostasisLipid MetabolismMelanomaMembrane ProteinsMitogen-Activated Protein KinasesMutationProtein Kinase InhibitorsAnimalsCell Line, TumorCell SurvivalEndoplasmic Reticulum StressHumansMiceXenograft Model Antitumor AssaysGTP PhosphohydrolasesMembrane ProteinsMitogen-Activated Protein KinasesNRAS protein, humanProtein Kinase Inhibitors
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Selective abrogation of S6K2 identifies lipid homeostasis as a survival vulnerability in MAPK inhibitor-resistant · full record | OpenQuestion